Treats heart failure. ANDA 215586, held by Ingenus Pharms LLC. Hydralazine Hydrochloride; Isosorbide Dinitrate.
As of Nov 16, 2026, ANDA 215586 (Isosorbide Dinitrate And Hydralazine Hydrochloride), held by Ingenus Pharms LLC, was first approved by FDA on Apr 6, 2022, with 0 approved supplements and 0 published complete response letters.
Isosorbide dinitrate and hydralazine hydrochloride tablets is a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: โ the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status Limitations of use: โ There is little experience in patients with NYHA class IV heart failure 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosorbide Dinitrate And Hydralazine Hydrochloride37.5MG;20MG ยท tablet;oral | Hydralazine Hydrochloride; Isosorbide Dinitrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters